Lanthanum Carbonate (BAY77-1931)
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hyperphosphatemia
Conditions
Hyperphosphatemia, Dialysis
Trial Timeline
Jun 1, 2005 → Oct 1, 2008
NCT ID
NCT00767637About Lanthanum Carbonate (BAY77-1931)
Lanthanum Carbonate (BAY77-1931) is a phase 2 stage product being developed by Bayer for Hyperphosphatemia. The current trial status is completed. This product is registered under clinical trial identifier NCT00767637. Target conditions include Hyperphosphatemia, Dialysis.
What happened to similar drugs?
2 of 15 similar drugs in Hyperphosphatemia were approved
Approved (2) Terminated (0) Active (13)
✅Ferric Citrate 1 gram Oral Tablet + Standard of care phosphate-lowering therapyAkebia TherapeuticsApproved
Hype Score Breakdown
Clinical
12
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01518387 | Phase 3 | Completed |
| NCT00767637 | Phase 2 | Completed |
Competing Products
20 competing products in Hyperphosphatemia